Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Saint Priest En Jarez – page 63

1 694 clinical trials in Saint Priest En Jarez, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint Priest En Jarez at a glance
1 694
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 694 trials in Saint Priest En Jarez

Open in trial search

Bacterial vaginosis

Not yet recruiting

Using a drug combination to treat vaginal flora abnormalities in pregnant women at high risk of preterm birth.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ceftriaxone
  • Sponsor:Assistance Publique Hopitaux De Marseille

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Ischaemic stroke

Not yet recruiting

Comparing tenecteplase and mechanical clot removal versus mechanical clot removal alone for adults with a large ischemic stroke

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Post procedural complication+3

Not yet recruiting

Study of lidocaine hydrochloride to reduce side effects from pain medication in patients undergoing open liver surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Rennes

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Pathios Therapeutics Limited

Plasma cell myeloma

Not yet recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.

Bone sarcoma

Not yet recruiting

Study of regorafenib as maintenance treatment after first-line therapy in patients with bone sarcomas without remaining disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Regorafenib
  • Sponsor:Centre Leon Berard

Thrombosis prophylaxis

Not yet recruiting

Comparing intermediate and standard doses of enoxaparin to prevent blood clots in patients with severe trauma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Tracheobronchitis bacterial

Not yet recruiting

A study testing inhaled amikacin compared to placebo in critically ill patients with ventilator-associated tracheobronchitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Chemical burn

Not yet recruiting

Treatment of Severe Eye Chemical Burns with Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells for Patients with Severe Ocular Chemical Burns

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Saint Priest En Jarez

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on head and neck cancer, multiple myeloma, and acute myeloid leukemia. Studies evaluating novel therapeutic approaches including targeted treatments and combination therapies.

  • Head & Neck Squamous Cell Carcinoma
  • Multiple Myeloma Treatment
  • Pancreatic Adenocarcinoma

Investigating breakthrough treatments and improving patient outcomes through innovative therapeutic strategies.

02 Autoimmune Disorders

Comprehensive research into inflammatory conditions and autoimmune diseases, with particular focus on Crohn's disease, rheumatoid arthritis, and novel treatment approaches.

  • Psoriatic Arthritis
  • Ulcerative Colitis
  • Sjögren's Syndrome

Evaluating advanced therapies and treatment combinations to improve disease management and patient quality of life.

03 Cardiovascular & Pulmonary Studies

Innovative research in pulmonary arterial hypertension and related conditions, exploring new therapeutic options and treatment strategies.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Cardiovascular Complications

Testing novel compounds and therapeutic approaches to address complex cardiovascular and pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.